Qureator (Curiochips) Inc., a biomedical company, focuses on the development of novel platforms and high-throughput disease models for precision medicine in areas of high unmet medical needs. The company provides Microphysiological Systems (MPS) which enable investigators to perform co-cultures of multiple cell types in 3D and high-throughput screenings for biomedical research and drug discovery. The company also offers a variety of patient-derived in vitro models in organs-on-chips which closely recapitulate the pathophysiology of diseases, thus can be efficiently applicable to target identification and compound screening, especially in the areas of fibrosis, oncology, angiogenesis, ocular disease, and vasculogenesis.